Recursion Pharmaceuticals

Salt Lake City, UT, United States All United States companies → — Founded 2013

AI Research Lab Biotech / Drug Discovery Specialty-Focused AI

Infectious Disease Neurology Oncology

Drug Discovery & Research

Public

Website Claim this company

Products

RECURSION

Recursion Pharmaceuticals

Drug Discovery & Research

Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to industrialize drug discovery through its AI-native, end-to-end platform, the Recursion OS.

Contact for pricing

See all 1 product →

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is a clinical-stage TechBio company that aims to revolutionize drug discovery and development by integrating artificial intelligence (AI) and machine learning with high-throughput automated wet-lab biology. The company’s proprietary platform, known as the Recursion Operating System (OS), generates, analyzes, and interprets massive biological and chemical datasets. This approach allows Recursion to explore novel biology, identify potential drug candidates, and advance them through development with increased speed and efficiency compared to traditional methods.

The Recursion OS is powered by proprietary multimodal data, purpose-built AI models, and bilingual teams proficient in both science and AI. It leverages robotics and computer vision to conduct millions of cell experiments weekly, feeding results back into the system for continuous improvement. The company has also built an in-house supercomputer, BioHive-1, and is developing BioHive-2 with NVIDIA, to train and deploy advanced AI models in computational biology and chemistry. Recursion’s pipeline includes investigational medicines in oncology, rare diseases, neuroscience, and immunology, with several programs in clinical stages. They also engage in strategic partnerships with major pharmaceutical companies like Bayer, Roche, Genentech, and Sanofi to expand their impact.

Recursion’s mission is to decode biology to radically improve lives by making drug discovery more programmable, data-driven, and scalable. They focus on indications with high unmet medical needs, such as familial adenomatous polyposis (FAP), advanced solid tumors, and hypophosphatasia. The company’s approach addresses key failure points in traditional R&D, including efficacy, safety, and clinical success, by using AI to map biology, generate chemistry, and simulate patient outcomes.

Focus Areas

AI-driven drug discovery rare diseases oncology inflammation & immunology neuroscience precision medicine

Business Intelligence

Technology

Recursion Operating System (OS), a full-stack, AI-native platform integrating automated wet labs, high-throughput cellular imaging (Cell Painting assay), deep learning, and a supercomputer (BioHive-2) to generate and analyze proprietary biological and chemical datasets (>60 petabytes).

What Physicians Need to Know

Drug Discovery & Development

Recursion Pharmaceuticals is industrializing drug discovery and development through its AI-driven Recursion Operating System (OS). This platform integrates automated wet labs, high-throughput screening, and advanced computational analysis to identify novel targets and design optimized molecules.

Rare Diseases

Recursion focuses on rare diseases with high unmet needs, leveraging its platform to identify potential first-in-class and best-in-class treatments. They have programs in clinical stages for conditions like Familial Adenomatous Polyposis (FAP) and Hypophosphatasia (HPP).

Oncology

The company has a significant focus on oncology, with multiple programs in clinical stages for various advanced solid tumors, lymphomas, and B-cell malignancies. They collaborate with partners like Bayer, Roche, and Genentech on precision oncology initiatives.

Neuroscience

Recursion is actively involved in neuroscience research and drug discovery, utilizing computational biology and data science to advance therapies for neurological and neurodegenerative diseases. They have partnerships in this area, including with Roche and Genentech.

Immunology & Inflammation

The company is engaged in immunology and inflammation research, employing its platform to identify and advance novel, targeted therapies for these disease areas.

AI/Machine Learning & Computational Biology/Chemistry

Recursion's core strength lies in its AI-native platform, the Recursion OS, which uses machine learning, deep learning, and computational biology/chemistry to analyze massive proprietary datasets (over 50 petabytes) generated from automated wet labs. This enables them to identify subtle cellular phenotypes and predict drug interactions.

Fibrotic Diseases

Recursion has a dedicated focus on fibrotic diseases, working with partners like Bayer to discover and develop new treatments for conditions affecting the lung, kidney, and heart. They use phenotypic screening to identify small molecules that can reverse disease-related fibrotic processes.

Physician Tip

Recursion Pharmaceuticals' approach offers several potential benefits for physicians. Their AI-driven platform aims to accelerate the discovery and development of novel medicines, potentially leading to new treatment options for diseases with high unmet needs, particularly in oncology and rare diseases. The company's focus on generating massive, high-quality biological and chemical datasets and using advanced AI to analyze them may lead to a deeper understanding of disease biology and more precisely designed therapies. Physicians may see the impact of this in faster identification of drug candidates and potentially improved efficacy and safety profiles due to the platform's ability to predict drug interactions and toxicity earlier in the development process. Recursion also emphasizes well-designed clinical trials and transparency, which can provide valuable data for treatment decisions.

Recursion Pharmaceuticals actively pursues strategic partnerships with leading pharmaceutical companies (e.g., Roche/Genentech, Bayer, Sanofi, Merck KGaA) and technology partners (e.g., NVIDIA, Google Cloud, Tempus, Helix). These collaborations are crucial for expanding their therapeutic reach, scaling and improving their AI drug discovery platform, accessing diverse datasets (including de-identified patient data), and securing non-dilutive funding. For physicians, this indicates a collaborative ecosystem that aims to integrate cutting-edge AI with established pharmaceutical expertise and real-world patient data, potentially leading to more robust and clinically relevant drug development.

At a glance

Founded 2013

HQ Salt Lake City, UT, United States · United States

CEO Najat Khan, Ph.D.

Funding Public

Products 1

Visit site

Products by Recursion Pharmaceuticals

1 product in the directory

RECURSION

Recursion Pharmaceuticals

Drug Discovery & Research

Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to industrialize drug discovery through its AI-native, end-to-end platform, the Recursion OS.

Contact for pricing

What the Web Says

Recursion Pharmaceuticals is a biotechnology company that utilizes AI, machine learning, and automation to accelerate drug discovery. They aim to identify new medicines more efficiently than traditional methods, focusing on areas like oncology, neuroscience, and immunology. While the company has secured significant partnerships with major pharmaceutical companies like Roche, Genentech, and Sanofi, and has several promising drug candidates in its pipeline, it has yet to bring an approved product to market. Employer reviews are mixed, with some praising the mission-driven culture and generous benefits, while others express concerns about work-life balance and management.

Overall: Mixed

Strengths

Mission-driven organization with a focus on innovative drug discovery.
Generous benefits and pay.
Lots of learning opportunities.
Strong partnerships with major pharmaceutical companies (e.g., Roche, Genentech, Sanofi).
Utilizes cutting-edge AI, machine learning, and automation in its drug discovery platform.
CEO is transparent and a great speaker.

Limitations

Poor work-life balance.
Lack of profitability and high cash burn rate.
Immature company with poor leadership and management concerns.
Lack of approved products and no candidates in Phase 3 studies yet.
Concerns about job security and advancement.
Some skepticism regarding the tangible success of their AI-driven drug discovery platform.

Based on reviews from: Indeed.com, Reddit, The Motley Fool, DirectorsTalk Interviews, MarketBeat, YouTube

Last updated: 2026-09-22

Videos

News, demos, and interviews about Recursion Pharmaceuticals.

Loading videos...

Videos load interactively. If none appear, search YouTube for Recursion Pharmaceuticals →

View all on YouTube

Press & Coverage

Stock Titan

Recursion inks $12M RNA model license with Tempus | RXRX 8-K Filing

Recursion Pharmaceuticals amended its agreement with Tempus AI, extending their data-access agreement, lowering future annual license fees, and granting Tempus a non-exclusive license to its TxFM RNA foundation model for oncology for a $12 million fee.

2026-09

TipRanks.com

Recursion, Tempus Expand AI and RNA Collaboration Agreements

Recursion Pharmaceuticals and Tempus AI expanded their AI and RNA collaboration, extending their data deal to six years, reducing Recursion's annual license fees, and licensing Recursion's TxFM RNA model to Tempus for oncology for $12 million.

2026-09

MarketBeat

Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference

Recursion Pharmaceuticals presented its AI-enabled drug discovery platform and progress on REC-4881 for familial adenomatous polyposis (FAP) at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its end-to-end AI engine and pipeline advancements.

2026-09

Quantum Zeitgeist

Tempus Commits $42 Million To Recursion Data Partnership

Tempus AI committed $42 million to Recursion Pharmaceuticals, restructuring their data partnership and extending it through November 2029, while Recursion granted Tempus a non-exclusive worldwide license to its TxFM RNA sequencing model.

2026-09

Recursion Pharmaceuticals, Inc.

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Recursion reported its second-quarter financial results, announcing that Genentech opted its first neuroscience target into an early discovery program and providing updates on its pipeline, including REC-4881 and REC-7735.

2026-08

Recursion Pharmaceuticals, Inc.

Recursion to Participate in Upcoming Investor Conferences

Recursion announced its participation in upcoming investor conferences, including the Bank of America 2026 SMID Cap Executive Insights Conference.

2026-08

Recursion Pharmaceuticals, Inc.

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion announced the grant of inducement awards on July 27, 2026, as permitted by Nasdaq Listing Rules.

2026-07

Recursion Pharmaceuticals, Inc.

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Recursion announced it would provide business updates and report its second-quarter 2026 financial results on August 5, 2026.

2026-07

Frequently Asked Questions

How does Recursion Pharmaceuticals leverage AI and machine learning in its drug discovery and development process?

Recursion Pharmaceuticals utilizes its proprietary AI-driven drug discovery platform, the Recursion OS, which integrates automated wet-lab experiments with machine learning and computational biology. This platform generates massive datasets of biological and chemical information, including over 50 petabytes of proprietary data from millions of cellular experiments. By applying advanced machine learning algorithms and large language models, Recursion aims to identify novel targets, design optimized molecules, and accelerate the drug discovery process from hit identification to IND-enabling studies, ultimately reducing costs and timelines compared to traditional methods.

What therapeutic areas is Recursion Pharmaceuticals focusing on, particularly concerning rare diseases, oncology, neuroscience, immunology, and fibrotic diseases?

Recursion Pharmaceuticals is advancing a pipeline of investigational medicines across various therapeutic areas with high unmet needs, including oncology, rare diseases, neuroscience, immunology, and inflammation. They have active collaborations with pharmaceutical companies like Bayer for fibrotic diseases and precision oncology, and with Roche and Genentech for neuroscience and an oncology indication. Recursion's platform is designed to decode complex biology in these areas, aiming to develop first-in-class and best-in-class treatments.

What are Recursion Pharmaceuticals' key partnerships, and how do they contribute to their drug discovery efforts?

Recursion Pharmaceuticals has established significant partnerships with leading biopharmaceutical and technology companies. Their therapeutic partners include Bayer Pharmaceuticals, Roche and Genentech, Sanofi, and Merck KGaA, Darmstadt, Germany, focusing on areas like fibrotic diseases, oncology, neuroscience, and immunology. They also have technology and data partnerships, notably with NVIDIA for supercomputing power and scaling foundation models in biology and chemistry, and with Helix for access to clinico-genomic data to train AI models and design biomarker strategies. These collaborations provide non-dilutive funding, access to expertise, and expand the scope and acceleration of their AI-driven drug discovery.

What is the current status of Recursion Pharmaceuticals' product pipeline and clinical trials?

Recursion Pharmaceuticals is a clinical-stage TechBio company with an advanced pipeline of potential treatments. Their pipeline includes programs in oncology (e.g., REC-1245 for solid tumors and lymphoma, REC-4881 for familial adenomatous polyposis) and rare diseases (e.g., REC-994 for cerebral cavernous malformation, though development for this has been discontinued). Several of their AI-developed drugs are nearing clinical trial readouts, with some in Phase 1b/2 and Phase 2 trials.

How does Recursion Pharmaceuticals address compliance and regulatory considerations for its AI-driven drug discovery?

While specific details on Recursion's compliance framework are not extensively publicized, as a clinical-stage biotechnology company, Recursion Pharmaceuticals operates under the regulatory requirements of the pharmaceutical industry. Their annual reports acknowledge that drug discovery and development, especially with AI, entails substantial compliance costs, and failure to comply could lead to significant liability. They are committed to patient safety and clinical excellence in their well-designed clinical trials.

What is the company's financial stability and outlook?

Recursion Pharmaceuticals is a publicly traded company (NASDAQ: RXRX) with a market capitalization of approximately $1.68 billion as of June 2026. They have secured significant funding through financing rounds and strategic partnerships, including over $500 million in upfront and milestone payments from collaborations. While the company has a substantial cash position, like many biotech companies, it faces ongoing cash burn and the inherent risks associated with early-stage research and the effectiveness of AI models in translating to successful clinical outcomes.

What kind of support and resources does Recursion Pharmaceuticals offer to healthcare providers or researchers interested in their platform or pipeline?

Recursion Pharmaceuticals is committed to advancing science and offers some of its data and models publicly for non-commercial use, including large-scale open-source datasets and foundation models. They also engage in strategic partnerships with academic research institutions. For specific inquiries regarding their investigational medicines, particularly for serious or life-threatening conditions where clinical trial enrollment isn't possible, Recursion will consider individual Expanded Access requests.